Efficacy of Small Subcutaneous Glucagon Dose to Treat Hypoglycemia in Adults With Type 1 Diabetes

Launched by INSTITUT DE RECHERCHES CLINIQUES DE MONTREAL · Apr 9, 2013

Keywords

ClinConnect Summary

In the unfortunate case of severe hypoglycaemia, glucagon is the first-line treatment because of its potent and rapid action starting as fast as 5 minutes after subcutaneous or intramuscular injection. Current instructions for the treatment of severe hypoglycaemia call for the immediate injection of 1 mg of glucagon subcutaneously or intramuscularly. Large dose of glucagon such as 1 mg subcutaneous is usually associated with undesirable side-effects such as nausea, vomiting, bloating and headache. Moreover, glucagon emergency kits are relatively expensive (around $100 per kit), thus increas...

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • Males and females ≥ 18 years of old
• • Clinical diagnosis of type 1 diabetes for at least two years.
• Exclusion Criteria:
• • Clinically significant nephropathy (MDRD \< 60 mL/min/1.73 m2).
• • Pregnancy
• • Severe hypoglycemic episode within two weeks of screening
• • Current use of glucocorticoid medication (except low stable dose)
• • Pheochromocytoma or primary adrenal insufficiency (e.g. Addison's disease)
• • Medical condition likely to interfere with study participation or with the ability to complete the trial by the judgment of the investigator.